MedTrace Logo

Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan

NCT06717191 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2025-07-30

No results posted yet for this study

Summary

This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Pakistan

Conditions

Interventions

DRUG

biosimilar insulin glargine

Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe

Sponsors & Collaborators

  • Baqai Institute of Diabetology and Endocrinology

    collaborator OTHER

  • Life for a Child Program, Diabetes Australia

    lead OTHER

Principal Investigators

  • Prof. Asher Fawwad · Baqai Insitute of Diabetology and Endocrinology (BIDE)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-09
Primary Completion
2024-06-15
Completion
2024-08-02
FDA Drug
Yes

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06717191 on ClinicalTrials.gov